← All trials
NCT05297448
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2022
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Mar 28, 2022
- Last posted
- Sep 23, 2022
- Enrollment
- 466
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bausch Health CompaniesLead sponsor
- Bausch Health CompaniesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.